Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q5H8C1
UPID:
FREM1_HUMAN
Alternative names:
Protein QBRICK
Alternative UPACC:
Q5H8C1; B7ZBX4; Q5VV00; Q5VV01; Q6MZI4; Q8NEG9; Q96LI3
Background:
FRAS1-related extracellular matrix protein 1, also known as Protein QBRICK, plays a pivotal role in epidermal differentiation and is essential for epidermal adhesion during embryonic development. This protein's involvement in the extracellular matrix underscores its importance in tissue integrity and development.
Therapeutic significance:
The association of FRAS1-related extracellular matrix protein 1 with diseases such as Bifid nose, with or without anorectal and renal anomalies, Manitoba oculotrichoanal syndrome, and Trigonocephaly 2, highlights its potential as a target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies for these congenital disorders.